JNJ-4804 Shows Promise for Hard-to-Treat Inflammatory Bowel Disease: New Drug Combination May Help Patients Who Have Run Out of Options

For millions of people living with inflammatory bowel disease (IBD), finding a treatment that works can feel like an endless battle. But new research presented at a major medical meeting offers hope, especially for those with the most stubborn forms of the disease. A study found that a combination antibody therapy called JNJ-4804 — which blends two existing drugs, guselkumab (Tremfya) and golimumab (Simponi) — produced better results than either medication alone in patients with highly refractory IBD. Refractory means the disease does not respond well to standard treatments.

The findings come from two phase IIb clinical trials, known as DUET-CD and DUET-UC, which were presented at the annual Digestive Disease Week (DDW) meeting. These trials focused on people with Crohn’s disease and ulcerative colitis, the two main forms of IBD. The results suggest that this combination approach could become a new lifeline for patients who have tried and failed multiple therapies.

What Is Inflammatory Bowel Disease and Why Is It So Hard to Treat?

IBD is a chronic condition that causes inflammation in the digestive tract. Crohn’s disease can affect any part of the digestive system, from the mouth to the anus, while ulcerative colitis is limited to the large intestine (colon) and rectum. Symptoms can include severe diarrhea, abdominal pain, fatigue, weight loss, and bloody stools. For many, these symptoms come and go in cycles of flare-ups and remission.

Treatment usually involves medications that calm the immune system, such as anti-inflammatory drugs, immune suppressants, and biologic therapies that target specific proteins involved in inflammation. However, not everyone responds to these treatments. Some patients are considered “refractory,” meaning their disease does not improve even after trying several different drug classes. For these individuals, the need for new options is urgent.

“We have patients who come into our offices who have been given everything on God’s green earth, and that is the group of patients with the biggest unmet need,” said Dr. Maria Abreu, a gastroenterologist at the F. Widjaja Inflammatory Bowel Disease Institute at Cedars-Sinai Medical Center in Los Angeles. She explained that when patients have already failed multiple treatments, doctors often have little left to offer.

How the DUET Studies Were Designed

The DUET-CD trial looked at patients with Crohn’s disease, while DUET-UC focused on those with ulcerative colitis. In both studies, researchers wanted to see if giving two different types of biologic drugs together would work better than giving either one alone. The combination drug, JNJ-4804, is a fixed-dose combination of guselkumab (an interleukin-23 inhibitor) and golimumab (a tumor necrosis factor-alpha inhibitor). These two drugs target different parts of the immune system’s inflammatory response.

A total of 693 patients were enrolled in the trials. About half of them had already failed two or more systemic therapies (treatments that work throughout the body). This group was labeled “highly refractory.” Patients were randomly assigned to receive one of several treatments: a placebo (inactive substance), golimumab alone, guselkumab alone, or JNJ-4804 at one of three different dose levels. The main goals of the study were to measure clinical remission (meaning symptoms were under control) and endoscopic response (meaning the lining of the intestine looked healthier during a scope exam).

Key Results: Combination Therapy Outperformed Single Drugs

In the overall study population (including both refractory and less refractory patients), high-dose JNJ-4804 showed clear advantages. At week 48, the clinical remission rate for high-dose JNJ-4804 was 50.8%, compared to 25.4% for golimumab alone and 42.5% for guselkumab alone. The difference between the combination and golimumab was statistically significant, meaning it was unlikely to be due to chance. The difference between the combination and guselkumab was not statistically significant, though it was numerically higher.

For endoscopic response, the pattern was similar: 38.1% of patients on high-dose JNJ-4804 showed improvement, versus 19.8% on golimumab and 33.9% on guselkumab.

But the most striking results came from the highly refractory subgroup — those who had already failed multiple treatments. In this group, 49.2% of patients on high-dose JNJ-4804 achieved clinical remission, compared to just 23.1% on golimumab and 27.3% on guselkumab. Endoscopic response rates were 33.3% for the combination, 12.3% for golimumab, and 20% for guselkumab.

“The results from DUET-CD are particularly promising because they show meaningful clinical and endoscopic improvements in patients who have exhausted existing options,” said Dr. Bruce E. Sands, a gastroenterologist at the Icahn School of Medicine at Mount Sinai in New York City, who presented the study at DDW.

What the Results Mean for Ulcerative Colitis Patients

In the DUET-UC trial, the results were also encouraging. In the overall population, high-dose JNJ-4804 led to a clinical remission rate of 41% at week 48, compared to 11.5% for golimumab and 34% for guselkumab. Again, the combination was significantly better than golimumab but not statistically different from guselkumab.

However, in the highly refractory group, the differences were more dramatic. Clinical remission rates were 26.7% for JNJ-4804, 2.1% for golimumab, and 16% for guselkumab. Dr. Abreu noted that this clear separation suggests the two drugs may work synergistically — meaning they boost each other’s effects — rather than just adding together.

“The overall results suggest [JNJ-4804] is really effective in the subset of patients that were on more than two mechanisms of action,” Abreu said. “It seems as if no patient comes to me that hasn’t been on at least two different medication types. So this is a really important need, both for Crohn’s and ulcerative colitis, and I think it would be an advance for the field.”

Safety: No Surprising Side Effects

One of the biggest concerns with combining two powerful immune-suppressing drugs is the risk of infections. When you dampen the immune system, you make it harder for the body to fight off germs. However, the researchers reported that safety events with JNJ-4804 were similar to those seen with each drug alone. Dr. Abreu emphasized that there was no increase in infections across the groups.

“Which is kind of the biggest worry that one would have expected immunologically,” she said.

This is reassuring for patients and doctors alike. It suggests that the combination may be no riskier than taking either drug individually, at least in the short term. Of course, longer-term safety data will be needed as the drug moves into larger trials.

Why This Matters for Patients and Doctors

For many people with IBD, the journey to find an effective treatment can be exhausting and frustrating. When the first, second, or even third drug fails, hope can fade. That is why this research is so important. It offers evidence that a combination approach might work when single drugs do not.

Dr. Victor G. Chedid, a gastroenterologist at the Mayo Clinic in Rochester, Minnesota, who was not involved in the DUET trials, explained that doctors already try combination therapies in practice, but without strong clinical trial data to back them up.

“What I usually see are patients who are in that category of refractory,” Chedid said. “And many a times, we find ourselves trying to get our patients on combination therapy — a JAK inhibitor plus an interleukin-23, or an anti-TNF with an interleukin-23, to try to salvage their colon or their small bowel — to get them in remission when they have had multiple therapies fail them already.”

He added that this is something doctors do out of necessity, but without solid evidence from clinical trials. “So this is something that we have to do — we try, and practice, without that solid clinical trial evidence,” he said.

The DUET studies change that. They provide prospective evidence — meaning data collected forward in time under controlled conditions — that can support these treatment approaches. This is especially important when dealing with insurance companies, who often require proof that a treatment is effective before they will cover it.

“Because in our current state, we appeal to insurance companies to get our patients who have refractory disease, and who are suffering, on combination therapy as the salvage approach, and we have to use retrospective data to help support our appeals with insurance companies,” Chedid noted.

What’s Next for JNJ-4804?

Johnson & Johnson, the company developing JNJ-4804, announced that based on these results, it will move forward with phase III trials. These larger studies will test the drug in adults with moderately to severely active Crohn’s disease and ulcerative colitis. If those trials are successful, the next step would be to seek approval from the U.S. Food and Drug Administration (FDA) and other regulatory agencies.

For now, the combination therapy is not yet available to the public. But the early results are generating excitement among specialists who treat IBD.

Practical Takeaways for Patients

If you or a loved one is living with IBD, especially a hard-to-treat form, here are some key points to keep in mind:

– New treatments are in the pipeline. Research is ongoing, and this combination therapy could become an option in the future.

• Talk to your doctor about your treatment history. If you have failed multiple therapies, you may be a candidate for clinical trials testing new approaches.
• Don’t lose hope. Even if current treatments aren’t working, new strategies — including combination therapies — are being studied and may offer relief.
• Stay informed. Follow trusted health news sources and talk to your gastroenterologist about emerging research.

The Bottom Line

The DUET-CD and DUET-UC trials offer promising evidence that combining two biologic drugs — guselkumab and golimumab — can help patients with highly refractory IBD achieve remission and heal their intestines. While more research is needed, these findings represent a significant step forward for a patient population that has long been underserved.

As Dr. Abreu put it, this combination could be “an advance for the field.” For the many patients who have run out of options, that advance cannot come soon enough.

Source: MedPage Today